Possibilities of intrapericardial immunotherapy with the use of interleukin-2 and allogenic LAK-cells in malignant pericardial effusions in the patients with breast and ovarian cancer
Malignant pericardial effusions often arise in patients with lung cancer, breаst cancer and ovarian cancer which is considered to be a dangerous complication of tumor. Intrapericardial chemotherapy is uneffective in generally and causes side effects. Here we show that intrapericardial IL-2/allogen. lymphokine activated killers (LAK) and interleukin-2 (IL-2) immunotherapy demonstrated the high efficacy in treatment of breаst and ovarian cancer patients with malignant pericardial effusions. The objective effect was 95,7% аnd 86,7% accordingly. These results indicate that intrapericardial immunotherapy might be one of the stages of combined treatment of such group of patients. The suggested type of biotherapy increases the survival and life quality of patients.